Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-09-01

AUTHORS

S Carlens, J Aschan, M Remberger, MS Dilber, O Ringdén

ABSTRACT

Low-dose cyclosporine (CsA), starting at 1 mg/kg/day i.v. with early discontinuation, and four doses of methotrexate (MTX), was given to 82 consecutive leukaemic patients receiving HLA-identical sibling marrow transplants. Retrospective controls (n = 40) received CsA, starting at 5–7.5 mg/kg/day i.v., given for 1 year, and MTX. In the low-dose group, the risk of acute GVHD grades I–II was 78% as compared to 57% among the controls (P < 0.01). the risk of acute gvhd grades iii–iv was 2% and 5%, respectively (ns). chronic gvhd occurred in 60% in the low-dose group and 24% in the controls (P < 0.001). extensive chronic gvhd did not differ between the groups (3% vs6%). In multivariate analyses, low-dose CsA was the only factor associated with acute GVHD grades I–IV (P = 0.02). Significant risk factors for chronic GVHD included low-dose CsA (P = 0.002) and CML (P = 0.03). Transplant-related mortality at 3 years post-BMT was 22% and 19%, in the low-dose group and controls, respectively (NS). The probability of relapse was 26% in the low-dose group and 53% in the controls (P = 0.06). In multivariate analysis, high-dose CsA was the strongest risk factor for relapse (P = 0.03). The 3-year relapse-free survival was 58% in the low-dose group and 43% in the controls (P = 0.1). More... »

PAGES

629-635

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954

DOI

http://dx.doi.org/10.1038/sj.bmt.1701954

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039560833

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10490728


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Host Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Histocompatibility Testing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden", 
            "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carlens", 
        "givenName": "S", 
        "id": "sg:person.0627641241.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627641241.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden", 
            "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aschan", 
        "givenName": "J", 
        "id": "sg:person.01030733311.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030733311.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Remberger", 
        "givenName": "M", 
        "id": "sg:person.0646371511.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646371511.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Department of Haematology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dilber", 
        "givenName": "MS", 
        "id": "sg:person.0611503663.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611503663.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden", 
            "Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ringd\u00e9n", 
        "givenName": "O", 
        "id": "sg:person.01145161711.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145161711.84"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999-09-01", 
    "datePublishedReg": "1999-09-01", 
    "description": "Low-dose cyclosporine (CsA), starting at 1\u2009mg/kg/day i.v. with early discontinuation, and four doses of methotrexate (MTX), was given to 82 consecutive leukaemic patients receiving HLA-identical sibling marrow transplants. Retrospective controls (n\u2009=\u200940) received CsA, starting at 5\u20137.5\u2009mg/kg/day i.v., given for 1 year, and MTX. In the low-dose group, the risk of acute GVHD grades I\u2013II was 78% as compared to 57% among the controls (P\u2009<\u20090.01). the risk of acute gvhd grades iii\u2013iv was 2% and 5%, respectively (ns). chronic gvhd occurred in 60% in the low-dose group and 24% in the controls (P\u2009<\u20090.001). extensive chronic gvhd did not differ between the groups (3% vs6%). In multivariate analyses, low-dose CsA was the only factor associated with acute GVHD grades I\u2013IV (P\u2009=\u20090.02). Significant risk factors for chronic GVHD included low-dose CsA (P\u2009=\u20090.002) and CML (P\u2009=\u20090.03). Transplant-related mortality at 3 years post-BMT was 22% and 19%, in the low-dose group and controls, respectively (NS). The probability of relapse was 26% in the low-dose group and 53% in the controls (P\u2009=\u20090.06). In multivariate analysis, high-dose CsA was the strongest risk factor for relapse (P\u2009=\u20090.03). The 3-year relapse-free survival was 58% in the low-dose group and 43% in the controls (P\u2009=\u20090.1).", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bmt.1701954", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "low-dose group", 
      "low-dose cyclosporine", 
      "low-dose CsA", 
      "chronic GVHD", 
      "acute GVHD", 
      "risk factors", 
      "day i.", 
      "HLA-identical sibling marrow transplants", 
      "multivariate analysis", 
      "acute GVHD grade III", 
      "GVHD grade III", 
      "extensive chronic GVHD", 
      "transplant-related mortality", 
      "high-dose CsA", 
      "marrow transplant recipients", 
      "relapse-free survival", 
      "doses of methotrexate", 
      "significant risk factors", 
      "strong risk factor", 
      "probability of relapse", 
      "risk of relapse", 
      "moderate GVHD", 
      "transplant recipients", 
      "early discontinuation", 
      "leukaemic patients", 
      "marrow transplant", 
      "grade III", 
      "GVHD", 
      "retrospective controls", 
      "relapse", 
      "methotrexate", 
      "only factor", 
      "CsA", 
      "cyclosporine", 
      "short duration", 
      "risk", 
      "group", 
      "discontinuation", 
      "patients", 
      "transplant", 
      "control", 
      "BMT", 
      "leukemia", 
      "years", 
      "mortality", 
      "factors", 
      "doses", 
      "recipients", 
      "CML", 
      "survival", 
      "duration", 
      "i.", 
      "analysis", 
      "probability"
    ], 
    "name": "Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia", 
    "pagination": "629-635", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039560833"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bmt.1701954"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10490728"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bmt.1701954", 
      "https://app.dimensions.ai/details/publication/pub.1039560833"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_308.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bmt.1701954"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701954'


 

This table displays all metadata directly associated to this object as RDF triples.

186 TRIPLES      20 PREDICATES      89 URIs      81 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bmt.1701954 schema:about N03e028dfac3b4046be7a96a837371430
2 N1040eb2284de4deca86882bd1add9183
3 N2ddb99e4958c48539b73447b9930d64b
4 N8b509ea48e864489ae024d6ca6a0930b
5 N8fc853827d4a4f16b46e5a1a9aab6728
6 N902d7902cd374f5988ef741451cd64b1
7 Naf0a7413ff114049a1581d78725df091
8 Ncdd9628f3ee44feb956e3ca727c37195
9 Nd4df6f8d7b1d46459e07ef789b82a32c
10 Nd63b71a362bb4baabb9da6a05605bdc5
11 anzsrc-for:11
12 anzsrc-for:1117
13 schema:author Naa604b3a42524e01bfff4d9bc9be7106
14 schema:datePublished 1999-09-01
15 schema:datePublishedReg 1999-09-01
16 schema:description Low-dose cyclosporine (CsA), starting at 1 mg/kg/day i.v. with early discontinuation, and four doses of methotrexate (MTX), was given to 82 consecutive leukaemic patients receiving HLA-identical sibling marrow transplants. Retrospective controls (n = 40) received CsA, starting at 5–7.5 mg/kg/day i.v., given for 1 year, and MTX. In the low-dose group, the risk of acute GVHD grades I–II was 78% as compared to 57% among the controls (P < 0.01). the risk of acute gvhd grades iii–iv was 2% and 5%, respectively (ns). chronic gvhd occurred in 60% in the low-dose group and 24% in the controls (P < 0.001). extensive chronic gvhd did not differ between the groups (3% vs6%). In multivariate analyses, low-dose CsA was the only factor associated with acute GVHD grades I–IV (P = 0.02). Significant risk factors for chronic GVHD included low-dose CsA (P = 0.002) and CML (P = 0.03). Transplant-related mortality at 3 years post-BMT was 22% and 19%, in the low-dose group and controls, respectively (NS). The probability of relapse was 26% in the low-dose group and 53% in the controls (P = 0.06). In multivariate analysis, high-dose CsA was the strongest risk factor for relapse (P = 0.03). The 3-year relapse-free survival was 58% in the low-dose group and 43% in the controls (P = 0.1).
17 schema:genre article
18 schema:isAccessibleForFree false
19 schema:isPartOf N6954c5409416417fb25baaa61dfe83be
20 Nff7315ca6ceb4365ab0b3b85b066dd25
21 sg:journal.1096890
22 schema:keywords BMT
23 CML
24 CsA
25 GVHD
26 GVHD grade III
27 HLA-identical sibling marrow transplants
28 acute GVHD
29 acute GVHD grade III
30 analysis
31 chronic GVHD
32 control
33 cyclosporine
34 day i.
35 discontinuation
36 doses
37 doses of methotrexate
38 duration
39 early discontinuation
40 extensive chronic GVHD
41 factors
42 grade III
43 group
44 high-dose CsA
45 i.
46 leukaemic patients
47 leukemia
48 low-dose CsA
49 low-dose cyclosporine
50 low-dose group
51 marrow transplant
52 marrow transplant recipients
53 methotrexate
54 moderate GVHD
55 mortality
56 multivariate analysis
57 only factor
58 patients
59 probability
60 probability of relapse
61 recipients
62 relapse
63 relapse-free survival
64 retrospective controls
65 risk
66 risk factors
67 risk of relapse
68 short duration
69 significant risk factors
70 strong risk factor
71 survival
72 transplant
73 transplant recipients
74 transplant-related mortality
75 years
76 schema:name Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia
77 schema:pagination 629-635
78 schema:productId N088e4422240a4f419d06acace9e079c8
79 N38db2a9ddefd477b84249a552b090462
80 N5d5f1413d0ae49f0bc10e3c691a5b0b5
81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039560833
82 https://doi.org/10.1038/sj.bmt.1701954
83 schema:sdDatePublished 2022-12-01T06:22
84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
85 schema:sdPublisher N5ec63c0e5348416cac56aa22d60cbc17
86 schema:url https://doi.org/10.1038/sj.bmt.1701954
87 sgo:license sg:explorer/license/
88 sgo:sdDataset articles
89 rdf:type schema:ScholarlyArticle
90 N03e028dfac3b4046be7a96a837371430 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Recurrence
92 rdf:type schema:DefinedTerm
93 N088e4422240a4f419d06acace9e079c8 schema:name dimensions_id
94 schema:value pub.1039560833
95 rdf:type schema:PropertyValue
96 N1040eb2284de4deca86882bd1add9183 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Cyclosporine
98 rdf:type schema:DefinedTerm
99 N2ddb99e4958c48539b73447b9930d64b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Graft vs Host Disease
101 rdf:type schema:DefinedTerm
102 N38db2a9ddefd477b84249a552b090462 schema:name doi
103 schema:value 10.1038/sj.bmt.1701954
104 rdf:type schema:PropertyValue
105 N5d5f1413d0ae49f0bc10e3c691a5b0b5 schema:name pubmed_id
106 schema:value 10490728
107 rdf:type schema:PropertyValue
108 N5ec63c0e5348416cac56aa22d60cbc17 schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 N6954c5409416417fb25baaa61dfe83be schema:issueNumber 6
111 rdf:type schema:PublicationIssue
112 N8b509ea48e864489ae024d6ca6a0930b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 N8fc853827d4a4f16b46e5a1a9aab6728 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Histocompatibility Testing
117 rdf:type schema:DefinedTerm
118 N902d7902cd374f5988ef741451cd64b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Risk
120 rdf:type schema:DefinedTerm
121 N9ba5f4b2931a49f6a6d5d14683916747 rdf:first sg:person.0611503663.38
122 rdf:rest Nbaeb180963fc49f48d542d674ca8bdc8
123 Na3d59c0bc1e04201822f71c5a461519d rdf:first sg:person.01030733311.14
124 rdf:rest Nc6714f9fd5144d0aa1ef7d82785fc6db
125 Naa604b3a42524e01bfff4d9bc9be7106 rdf:first sg:person.0627641241.94
126 rdf:rest Na3d59c0bc1e04201822f71c5a461519d
127 Naf0a7413ff114049a1581d78725df091 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Disease-Free Survival
129 rdf:type schema:DefinedTerm
130 Nbaeb180963fc49f48d542d674ca8bdc8 rdf:first sg:person.01145161711.84
131 rdf:rest rdf:nil
132 Nc6714f9fd5144d0aa1ef7d82785fc6db rdf:first sg:person.0646371511.36
133 rdf:rest N9ba5f4b2931a49f6a6d5d14683916747
134 Ncdd9628f3ee44feb956e3ca727c37195 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Leukemia
136 rdf:type schema:DefinedTerm
137 Nd4df6f8d7b1d46459e07ef789b82a32c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Bone Marrow Transplantation
139 rdf:type schema:DefinedTerm
140 Nd63b71a362bb4baabb9da6a05605bdc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Time Factors
142 rdf:type schema:DefinedTerm
143 Nff7315ca6ceb4365ab0b3b85b066dd25 schema:volumeNumber 24
144 rdf:type schema:PublicationVolume
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
149 schema:name Public Health and Health Services
150 rdf:type schema:DefinedTerm
151 sg:journal.1096890 schema:issn 0268-3369
152 1476-5365
153 schema:name Bone Marrow Transplantation
154 schema:publisher Springer Nature
155 rdf:type schema:Periodical
156 sg:person.01030733311.14 schema:affiliation grid-institutes:grid.24381.3c
157 schema:familyName Aschan
158 schema:givenName J
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030733311.14
160 rdf:type schema:Person
161 sg:person.01145161711.84 schema:affiliation grid-institutes:grid.24381.3c
162 schema:familyName Ringdén
163 schema:givenName O
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145161711.84
165 rdf:type schema:Person
166 sg:person.0611503663.38 schema:affiliation grid-institutes:grid.24381.3c
167 schema:familyName Dilber
168 schema:givenName MS
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611503663.38
170 rdf:type schema:Person
171 sg:person.0627641241.94 schema:affiliation grid-institutes:grid.24381.3c
172 schema:familyName Carlens
173 schema:givenName S
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627641241.94
175 rdf:type schema:Person
176 sg:person.0646371511.36 schema:affiliation grid-institutes:grid.24381.3c
177 schema:familyName Remberger
178 schema:givenName M
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646371511.36
180 rdf:type schema:Person
181 grid-institutes:grid.24381.3c schema:alternateName Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden
182 Department of Haematology, Huddinge University Hospital, Huddinge, Sweden
183 schema:name Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Huddinge, Sweden
184 Department of Clinical Immunology, Huddinge University Hospital, Huddinge, Sweden
185 Department of Haematology, Huddinge University Hospital, Huddinge, Sweden
186 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...